Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 28 01:25PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week8.55%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month31.40%
Income- PEG- EPS next Q- Inst Own- Short Float / Ratio- / 0.19 Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.00M Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price30.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range7.82 - 19.30 Perf YTD-28.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-44.71% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low36.45% ATR0.55
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)56.34 Volatility1.92% 4.25%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.06 Prev Close10.56
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume23.42K Price10.67
Recom1.00 SMA2017.08% SMA509.35% SMA2009.35% Volume1,029 Change1.04%
Date Action Analyst Rating Change Price Target Change
Oct-24-23Initiated Cantor Fitzgerald Overweight $30
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.